These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27207777)

  • 21. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Yin L; Zeng Y; Zeng R; Chen Y; Wang TL; Rodabaugh KJ; Yu F; Natarajan A; Karpf AR; Dong J
    Oncogene; 2021 Dec; 40(50):6772-6785. PubMed ID: 34799660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin-like growth factor 2 silencing restores taxol sensitivity in drug resistant ovarian cancer.
    Brouwer-Visser J; Lee J; McCullagh K; Cossio MJ; Wang Y; Huang GS
    PLoS One; 2014; 9(6):e100165. PubMed ID: 24932685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer.
    Jiang J; Wang S; Wang Z; Cai J; Han L; Xie L; Han Q; Wang W; Zhang Y; He X; Yang C
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):295-305. PubMed ID: 32743678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survivin siRNA increases sensitivity of primary cultures of ovarian cancer cells to paclitaxel.
    Kar R; Palanichamy JK; Banerjee A; Chattopadhyay P; Jain SK; Singh N
    Clin Transl Oncol; 2015 Sep; 17(9):737-42. PubMed ID: 26033427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3.
    Jeong JY; Kang H; Kim TH; Kim G; Heo JH; Kwon AY; Kim S; Jung SG; An HJ
    Cancer Lett; 2017 Feb; 386():168-178. PubMed ID: 27887917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
    Zhou Y; Han C; Li D; Yu Z; Li F; Li F; An Q; Bai H; Zhang X; Duan Z; Kan Q
    Sci Rep; 2015 May; 5():10433. PubMed ID: 25990212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
    Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
    Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
    Zhang S; Lu Z; Mao W; Ahmed AA; Yang H; Zhou J; Jennings N; Rodriguez-Aguayo C; Lopez-Berestein G; Miranda R; Qiao W; Baladandayuthapani V; Li Z; Sood AK; Liu J; Le XF; Bast RC
    PLoS One; 2015; 10(7):e0131833. PubMed ID: 26146988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
    PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
    Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
    Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
    [No Abstract]   [Full Text] [Related]  

  • 34. EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
    Bradley A; Zheng H; Ziebarth A; Sakati W; Branham-O'Connor M; Blumer JB; Liu Y; Kistner-Griffin E; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Landen CN; Eblen ST
    Carcinogenesis; 2014 May; 35(5):1100-9. PubMed ID: 24379240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.
    Li X; Guan W; Liu H; Yuan J; Wang F; Guan B; Chen J; Lu Q; Zhang L; Xu G
    Apoptosis; 2024 Oct; 29(9-10):1546-1563. PubMed ID: 38615082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical role of CDK11(p58) in human breast cancer growth and angiogenesis.
    Chi Y; Huang S; Peng H; Liu M; Zhao J; Shao Z; Wu J
    BMC Cancer; 2015 Oct; 15():701. PubMed ID: 26470709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
    Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
    PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
    Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
    Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.
    Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T
    Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.